SII and DNDi will develop a work plan to implement research and development, Phase 3 clinical trials, and access activities, ...

SII partners with DNDi to develop affordable dengue treatment, aiming to save lives in LMICs and endemic countries.

Serum Institute and DNDi sign MoU to develop and scale a dengue monoclonal antibody vaccine with Phase 3 trials in India, ...

Serum Institute of India and DNDi collaborate to accelerate development of an affordable dengue monoclonal antibody treatment ...

Serum Institute of India and DNDi partner to develop affordable dengue treatment, conducting Phase III trials in multiple countries.

The Serum Institute of India (SII), the world’s largest vaccine manufacturer and Drugs for Neglected Diseases initiative ...

The Serum Institute of India collaborates with the Drugs for Neglected Diseases initiative to develop a monoclonal antibody ...

Japanese scientists have achieved a breakthrough by developing a universal, virus-free artificial blood substitute. This innovation, based on hemoglob ...

New Delhi: Union Minister of State for AYUSH and Health and Family Welfare Prataprao Jadhav has called Ayurveda "India's soft power", and claimed that it has a global acceptance based on strong ...

Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation in the graft versus host ...

Highlighting the importance of the conclave, Nadda said it is a "pioneering initiative that seeks to consolidate rich ...